There are several options available for treatment of advanced or metastatic disease depending upon the line of therapy, the type of histology (squamous versus adenocarcinoma) and the presence of biomarkers (human epidermal growth factor receptor 2 (HER2), MSI and PD-L1. Here, ERBB2 is linked to adenocarcinoma.